ATC Group: B01AE06 Bivalirudin

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of B01AE06 in the ATC hierarchy

Level Code Title
1 B Blood and blood forming organs
2 B01 Antithrombotic agents
3 B01A Antithrombotic agents
4 B01AE Direct thrombin inhibitors
5 B01AE06 Bivalirudin

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 0.25 g

Active ingredients in B01AE06

Active Ingredient Description
Bivalirudin

Bivalirudin is a direct and specific thrombin inhibitor that binds both to the catalytic site and the anion-binding exosite of fluid-phase and clot-bound thrombin.

Related product monographs

Title Information Source Document Type  
ANGIOMAX Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
Angiox 250mg powder for concentrate for solution for injection or infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Estonia (EE)

Lithuania (LT)

New Zealand (NZ)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.